Table 2: Clinical and parasitological therapeutic outcome after PCR correction.

 

AL

ASMQ

DHAP

P (1)

P (2)

 Per-protocol day 28

 

 

 

 

 

 

 

 

 

Before PCR corrections (%)

After PCR corrections (%)

Before PCR corrections (%)

After PCR corrections (%)

Before PCR corrections (%)

After PCR corrections (%)

 

 

ETF

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

 

LCF

2 (2.9)

1 (1.4)

4 (5.7)

2 (2.9)

1 (1.4)

1 (1.4)

 

 

LPF

7 (10.1)

1 (1.4)

3 (4.3)

0 (0.0)

4 (5.7)

0 (0.0)

 

 

ACPR (N; IC95%)*

60 (86.9) (IC95%; 85.3-88.5%)

67 (97.1) (IC95% 96.8-97.4%)

63 (90.0) (IC95%; 88.8-91.2%)

68 (97.1) (IC95%; 96.8-97.4%)

65 (92.9) (IC95%; 92.1-93.7%)

69 (98.6) (IC95%; 98.4-98.8%)

0.002

0.002

 

 

Total

69

69

70

70

70

70

 

 

 Per-protocol day 42

 

 

 

 

 

 

 

 

LCF

4 (6.0)

1 (1.4)

0 (0.0)

0 (0.0)

1 (1.4)

0 (0.0)

 

 

LPF

9 (13.0)

3 (4.5)

11 (16.8)

2 (2.9)

5 (7.2)

0 (0.0)

 

 

ACPR (N; IC95%)*

56 (81.1) (IC95% 78.8-83.4%)

65 (94.2) (IC95%; 93.5-94.9%)

57 (83.8) (IC95%; 81.8-85.8%)

66 (97.1)(IC95%; 96.8-97.4%)

63 (91.3) (IC95%; 90.3-92.3%)

70 (100)

0.01

0.003

Total

69

69

68

68

70

70

 

 

ACPR

D7-D42

84% (IC 95%; 83.3- 84.7%)

95.6% (IC95%; 95.3-96.0%)

86.9% (IC95%; 86.1-87.7%)

97.1% (IC95%; 96.8-97.4%)

92.1% (IC95%; 91.9-92.3%)

99.3% (IC95%; 99.1-99.6%)

0.004

0.003

Per-protocol efficacy: Proportion of adequate clinical and parasitological response; *Confidence interval at 95 % (binomial exact method); (1) Compare DHAP vs. AL; (2) Compare DHAP vs. ASMF.